Answers are grounded in this paper and cite their sources.
Over the past 2 decades, the United States (US) has experienced an unprecedented increase in overdose deaths as well as infectious disease consequences primarily associated with the misuse and injection of prescription opioid pain relievers and illicit opioids such as heroin and illicitly manufactured fentanyl. Indeed, injection drug use (IDU) and its myriad health impacts are a public health crisis, with an estimated 1 million people (0.24–0.59% of the noninstitutionalized population of the US) reporting IDU in the prior year (see Bradley in this supplement). Increases in IDU have led to outbreaks of human immunodeficiency virus (HIV) and higher rates of infections transmitted during nonsterile injection events, especially hepatitis C virus (HCV) and invasive bacteria and fungi that cause endocarditis, osteomyelitis, and skin and soft tissue infections [1–4]. In this supplement, “Infectious Diseases and Injection Drug Use: Public Health Burden and Response,” a number of authors (see names listed in parentheses throughout) highlight the changing environment for IDU-associated infections and the implications for surveillance, prevention, and control. Although the articles in this supplement were submitted prior to the coronavirus disease 2019 (COVID-19) pandemic, people who inject drugs (PWID) have in no way been spared. The social distancing measures that helped slow the spread of severe acute respiratory syndrome coronavirus 2 may increase feelings of anxiety and loneliness among PWID while making it more difficult to obtain prevention, treatment, and social services. Although the full impact of the pandemic on PWID has not been defined, PWID are likely at risk for infection and severe disease, due to high rates of comorbid health conditions, homelessness, and other suboptimal social conditions [5–11]. The supplement begins with the Infectious Diseases Society of America (IDSA) and the HIV Medicine Association (HIVMA) calling for a new paradigm to address the opioid crisis and IDU-associated infections. IDSA and HIVMA recommend changes to federal and state policies to expand harm reduction programs and services; improve disease surveillance, diagnosis, and linkage to care; and integrate treatment for IDU-associated infections with treatment for substance use disorders in hospitals, community-based organizations, and correctional settings. The authors cite an address by Jonathan Mann in 1998 and apply his words to the opioid crisis: “ ‘When the history of AIDS and the global response is written, our most precious contribution may well be that, at a time of plague, we did not flee, we did not hide, we did not separate ourselves.’ This time is no different—it is our epidemic too.” The opioid crisis creates challenges for the national initiative to End the HIV Epidemic [12] by increasing IDU-associated HIV infections and outbreaks [1]. Since 2016, IDU-associated outbreaks of HIV have been reported in Indiana, Massachusetts, Oregon, Pennsylvania, Washington State, West Virginia, and the Northern Kentucky/Cincinnati metropolitan area (Lyss, Kim, and Tumpney). In an analysis of 529 349 Centers for Disease Control and Prevention (CDC)–funded HIV tests among PWID during 2012–2017, the percentage with newly diagnosed HIV infections increased by 4% per year, with particularly high increases among PWID who were <30 years old, male, and white (Rao). The opioid crisis is also undermining efforts to reduce the US burden of HCV infection [13, 14]. Despite the availability of curative therapy, rates of hepatitis C are rising, with acute cases of infection more than tripling between 2010 and 2017 [15]. Until recently, persons born between 1945 and 1965 made up the group with the largest prevalence of HCV infection. Over the past decade, however, HCV infection prevalence has increased among all ages, especially persons aged 20–45 years, largely driven by rising IDU [13, 16–18]. This group of younger individuals is more likely to be rural, white, and female than prior high-burden populations. Cases of perinatal HCV infection also are increasing [17, 18]. In 2020, to expand identification of HCV infection among a broader population, the CDC began recommending that all adults in the US be tested at least once for HCV infection, and that obstetricians screen for HCV infection during each pregnancy [19]. The supplement includes evaluations of prevention interventions for IDU-associated HIV and hepatitis C (Johnson and Krebs) and an example of a statewide vulnerability assessment that can help target interventions to geographic areas most likely to experience infections (Wesner). An overview of published reviews found that syringe services programs (SSPs) and opioid agonist treatment were associated in quasiexperimental studies with significant favorable differences in reducing risk behavior between people who used these services and people who did not (Johnson). Notably, SSPs were associated with a 46%–54% reduction in odds of sharing injection equipment and a 50% reduction in odds of acquiring new HIV infections. An economic modeling study of HIV microepidemics in 6 US cities reported that expanding access to multiple interventions, especially medication for opioid use disorder (MOUD) and rapid HIV testing, could reduce HIV incidence by 8%–54% (depending on the city) within 10 years, while scaling up SSPs would be cost-effective in cities with currently low levels of syringe distribution (Krebs). Studies conducted in a large opioid treatment program (OTP) in New York City found that hepatitis C incidence was lower among patients who more consistently received MOUD and engaged in OTP services and that ending the hepatitis C epidemic among PWID will require expansion of HCV infection treatment coverage (Jordan, Cleland, Schackman, Wyka, Perlman, and Nash; Jordan, Cleland, Wyka, Schackman, Perlman, and Nash). Other studies in this supplement investigated ways to improve HIV and hepatitis C testing and linkage to care among PWID in rural (Allen, Sherbuk, and Lee) and urban (Assoumou and Rowan) areas. For example, an interdisciplinary telehealth model facilitated provider training and led to improved health outcomes in a medically underserved area in Appalachia (Sherbuk). Two studies examined whether point-of-care (POC) or laboratory-based testing resulted in higher rates of linkage to care. Patients who received rapid POC testing for HCV and HIV at a detoxification center in Boston were more likely to receive test results within a 2-week period (Assoumou). However, only 6% of those with positive results were linked to care. In contrast, a study conducted in mostly rural areas of Alabama concluded that an electronic medical record (EMR)–based testing strategy for HCV—laboratory-based serology testing coupled with patient alerts based on EMRs—was more likely to lead to confirmatory RNA testing (odds ratio [OR], 2.07; P < .0001) and linkage to care (OR, 1.51; P < .0001), likely because HCV antibody–positive samples were automatically sent for nucleic acid testing (Rowan). Active participation of a dedicated linkage coordinator and co-location of prevention and treatment services at drug treatment centers and Federally Qualified Health Centers also enhanced linkage to care. Several studies found that psychological, social, and economic factors (eg, mental illness, homelessness, and medical coverage) influenced access to treatment for opioid use disorder and IDU-associated HIV and HCV infections (Winetsky, Adams, Metcalfe, and Lewis). One article describes how a community’s HIV clinical service model was reconfigured to address the medical needs of homeless persons who inject drugs (Metcalfe); another found that PWID living in states with expanded Medicaid coverage are more likely to be insured, to be tested for HIV and HCV infection, and to use MOUD to reduce opioid use (Lewis). By introducing organisms from the skin microbiome into the bloodstream, IDU can lead to bacterial and fungal infections such as infective endocarditis (IE), epidural abscess, skin and soft tissue infections, osteomyelitis, bacteremia and fungemia, and septic arthritis. The occurrence of these infections is growing, particularly in younger adults, with cases of severe infection increasing and often requiring prolonged treatment and hospitalization [3, 20–25]. The most common organisms include Staphylococcus aureus (including methicillin-resistant S. aureus), group A Streptococcus, and Candida species [21]. In addition to injection, other associated practices and social factors (eg, homelessness, lack of access to hygiene) may also contribute to person-to-person transmission of potentially pathogenic organisms into the PWID population [24, 25], including antibiotic-resistant organisms. New initiatives are urgently needed to reduce rates of invasive infections among PWID. Historically, evaluation of the national burden of IDU-associated infections has been difficult, because many invasive bacterial and fungal infections are not reportable to CDC or state health departments. A review of estimates of the national public health burden of IDU-associated bacterial and fungal diseases reports that estimated numbers of hospital admissions for IDU-associated IE ranged from 2900 in 2013 to >20 000 in 2017 (See). In addition, an estimated 155 000–540 000 IDU-associated skin infections occur annually among hospitalized and nonhospitalized patients. This supplement also includes surveillance studies that document recent large increases in IDU-associated invasive infections in different localities (de Gijsel, Rossow, Coyle, and Sredl). For example, a study of IDU-associated IE at a hospital in New England reported a 440% increase in hospitalizations for drug use–associated IE from April 2011 to December 2017 (de Gijsel). Other studies reported rising rates of IDU-associated candidemia in a rural community in Tennessee (from 6.1% in 2014 to 14.5% in 2018) and of hospitalizations for invasive drug-related infections in North Carolina (from 1.5% in 2010 to 13.1% in 2018) and Michigan (increases of 33% in IE and 35% in osteomyelitis between 2016 and 2018) (Rossow, Coyle, and Sredl). The study from Tennessee reported that many Candida infections identified among PWID were healthcare-associated infections related to outpatient use of a peripherally inserted central catheter (PICC) to treat an initial bacterial infection. The study from Michigan reported that hospitalizations for IDU-associated infections involved long hospital stays, significant mortality rates (5.5%), and healthcare costs of >$1.3 billion. The US is experiencing large increases in reported sexually transmitted diseases (STDs), particularly gonorrhea, primary and secondary syphilis, and chlamydia [26]. These increases may be due in part to high-risk sexual behaviors associated with drug use (eg, unprotected sex, sex with multiple partners, or selling sex to pay for drugs) [27]. Cases of congenital syphilis nearly tripled from 2014 to 2018 (462 cases in 2014 to 1306 cases in 2018) [26]. Risky sexual behavior among PWIDs is also a risk factor for HIV infection [28]. The supplement includes research about IDU-associated STDs in 2 population groups: early syphilis among PWID in Missouri (see Reno) and sexually transmitted HIV among people who use methamphetamine in Los Angeles (see Gorbach). The study from Missouri reported that the number of cases of early syphilis in the state grew by 365% between 2012 and 2018, with the largest increase in small metropolitan and rural areas (1170%). A higher percentage of early syphilis was found among PWIDs in nonurban areas (12%–15%) than in St Louis (2.3%) or Kansas City (5.1%), the major urban areas in the state. The study from Los Angeles evaluated risk factors for acquiring and transmitting HIV among a cohort of young men who have sex with men (Gorbach). Compared with cohort members who use methamphetamine without reporting injection use, use other substances, or do not use drugs, those who inject methamphetamine reported a higher prevalence of new sex partners, a higher proportion of HIV positivity, a lower proportion of viral suppression among those with HIV infection, and a higher proportion of other STDs. A common theme of the articles in the supplement is the largely unmet need for integrated treatment of IDU-associated infectious diseases and substance use disorders. The benefits of integrated treatment are described in commentaries that discuss treating opioid use disorders in patients served by the national Ryan White HIV/AIDS Program, especially in states with rural HIV epidemics (Chavis), and using telemedicine and long-acting medications to provide integrated treatment in jails and prisons (Krsak). This supplement also includes research articles that evaluate integrated treatment strategies and protocols and that identify barriers to MOUD (Price, Eaton, Cooksey, and Marks). One study concluded that combining addiction treatment and parenteral antibiotic therapy on an outpatient basis is feasible and safe; all study participants who qualified for outpatient treatment completed the course of antibiotic therapy, with 30% of participants experiencing a 30-day readmission and 15% resuming IDU; however, no overdose deaths or PICC line complications were reported (Price). A second study confirmed that a standardized, hospital-based protocol increased access to MOUD for PWIDs with severe infections (Eaton). However, uptake of MOUD was <50%, due to staffing shortages, opt-outs by patients, and other issues that led to missed opportunities for addiction medicine consultations. Another healthcare protocol designed to improve care for PWIDs hospitalized with IE reduced 90-day all-cause readmission and 12-month all-cause mortality (Cooksey). However, a significant number of patients left the hospital against medical advice, likely due to concerns about social stigma, concomitant mental illness, unwillingness to comply with restrictions imposed by the protocol, and inadequate management of opioid withdrawal. In addition, a comparison study of MOUD treatment strategies found that use of either buprenorphine or methadone was associated with increased completion rates for parenteral antibiotic therapy (64.1% vs 46.2%) and that continuation of MOUD after discharge was associated with lower 90-day readmissions (Marks). The studies presented in this supplement underscore the public health burden and challenges of rising IDU and related harms in the United States. Encouragingly, numerous articles in the supplement also provide insights into prevention, treatment, and control strategies to counter this public health crisis. These strategies aim to reduce IDU-associated infections by preventing the initiation of IDU; integrating treatment for IDU-associated infections with MOUD to help PWID stop injecting; implementing preventive measures such as vaccination and prophylaxis for IDU-associated bacterial infections; linking PWIDs to social services that address underlying factors that lead to or perpetuate drug use; and expanding the use of safer injection practices, including provision of sterile injection equipment. A new paradigm to address the public health crisis of opioid and other IDU and associated infectious diseases must focus on all aspects of prevention and control, while improving disease surveillance and ensuring access to integrated treatment and care. The public health and healthcare communities can join in a common effort to mobilize the science, resources, and determination to meet the challenges ahead. Supplementary materials are available at The Journal of Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author. Disclaimer. The opinions expressed by authors contributing to this supplement do not necessarily reflect the opinions of the US Department of Health and Human Services, the Public Health Service, or the Centers for Disease Control and Prevention. Supplement sponsorship. This supplement is sponsored by the Centers for Disease Control and Prevention. Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
No takes yet. Share an insight, caveat, or question.
Levitt et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: